TARA · Protara Therapeutics, Inc. · Investor Relations

$2.56 +0.23 (+9.87%)

Russell 2000 member Rebalance outlook locked

Market Cap

$137.69M

59.10M

Volume · Oct 20 1.49M Avg daily vol (3M) 882.43K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date	Event	Type
2026-09-15	H.C. Wainwright 28th Annual Global Investment Conference	Conference
2026-06-12	2026 Annual Meeting of Shareholders	Shareholder meeting
2026-05-26	TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA	Webcast
2026-05-19	Protara Therapeutics Lymphatic Malformations KOL Webinar	Event
2026-05-19	ISSVA poster: STARBORN-1: Interim Efficacy and Safety Data in Pediatric Participants with Macrocystic and Mixed-Cystic Lymphatic Malformations Treated with Intracystic Injection of TARA-002	Event
2026-05-19	AUA poster: ADVANCED-2 (Cohort A): Interim 12-Month Efficacy and Safety Data in BCG-Naïve Participants With High-Grade Non-Muscle Invasive Bladder Cancer	Event
2025-04-26	AUA poster: Preliminary Efficacy and Safety Results From ADVANCED-2: A Phase-2 Open-label Study of Intravesical TARA-002 In Adults With High-grade Non-muscle Invasive Bladder Cancer	Event
2024-12-05	SUO Poster - ADVANCED-2: Phase 2 Open-label Study to Evaluate Safety and Anti-tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer	Event
2022-05-12	ISSVA 2022 Poster – Retrospective Analysis of a Randomized Study and Open-Label Study to Evaluate the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations	Event

Source: https://protaratx.com/investors/

Key facts CIK 1359931 CUSIP 74365U107 13F (30d) 4 filings 4 filers Visit website Investor relations